Please login to the form below

Not currently logged in
Email:
Password:

Lilly partners on antiplatelet programme

Eli Lilly and Daiichi Sankyo have announced a collaboration with Accumetrics to educate doctors about a test involving antiplatelet therapy

Eli Lilly and Company and Daiichi Sankyo, its development and marketing partner on the antiplatelet medication Effient (prasugrel), have entered into a US collaboration with the diagnostics company Accumetrics to educate doctors about a rapid test that assesses patients' response to antiplatelet therapy.

The campaign comes on the heels of a clinical alert issued last month by the American College of Cardiology Foundation and American Heart Association in response to the addition of a boxed warning to the blockbuster antiplatelet therapy Plavix (clopidogrel bisulfate), which is marketed by sanofi-aventis (SA) and Bristol-Myers Squibb (BMS).

The warning states that due to genetic factors, some patients taking Plavix may have an increased risk of thrombotic cardiovascular events and some may have reduced response to the drug; the medical societies' alert stressed the variability in response in patients with acute coronary syndrome who are managed with the angioplasty and stenting technique known as PCI.

At the time, Lilly stressed that the genetic variation that complicated response to Plavix did not have the same effect for Effient, a difference that could give the Lilly drug an edge in the marketplace.

The new partnership promotes Accumetrics' point-of-care VerifyNow System as a way for doctors to determine patients' response to antiplatelet agents, including Plavix, Effient and others. The programme will educate doctors about the factors that affect response to antiplatelet medication and how platelet function testing works.

13th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics